Biogen Inc. filed this amendment to its May 14, 2026, Form 8-K to clarify that the acquisition of Apellis Pharmaceuticals, Inc. does not constitute a "significant" acquisition under Regulation S-X. Consequently, the company determined that it is not required to file financial statements of the acquired business or pro forma financial information. All other disclosures from the original report remain unchanged. Biogen is a biotechnology company focused on neurological and immunology therapies.
